Status:
COMPLETED
Basal Insulin for Type 2 Diabetes Patients Treated in Outpatient Clalit Clinics
Lead Sponsor:
Sanofi
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
21+ years
Brief Summary
Treatment of diabetes mellitus type II with basal insulin, for patients treated in Clalit outpatient clinics that are not adequately controlled with current treatment.
Detailed Description
Patients with diabetes treated in outpatient clinics will be recruited by their primary care physician. Recruitment period will be 3 months per center and each patient will be followed for 7 months Di...
Eligibility Criteria
Inclusion
- Type II Diabetic patients
- HbA1c \>8.0% (result from preceding 4 months)
- Written informed consent
- Life expectancy of at least 1 year.
- Patients' agree to discontinue current long acting insulin (if applicable).
- Patients who according to their GP are eligible to the study.
Exclusion
- Type I diabetes
- Pregnancy and\\or lactation.
- Allergy to basal insulin
- Patients suffering from a disease that requires repeated hospitalizations E.g.: severe CHF, sever renal failure, active malignancy.
- Patients who are not able to give consent.
- Patients face difficulties in mobility and/or verbal communication with the treating physician.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
1229 Patients enrolled
Trial Details
Trial ID
NCT00726674
Start Date
August 1 2008
End Date
January 1 2012
Last Update
March 8 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis Administrative Office
Netanya, Israel